
Pipeline
We are working to deliver best-in-class pan-variant tyrosine kinase inhibitors (TKIs) to fight cancer.
Our pipeline focuses on developing next-generation TKIs that address treatment resistance in cancer.
Program/Target
Indication
Stage
Discovery
IND-Enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights

We are targeting cancers where current therapies are limited by the burden of treatment resistance.
LEARN ABOUT OUR DISEASE FOCUS